Immunovant (IMVT) Projected to Post Quarterly Earnings on Friday

Immunovant (NASDAQ:IMVT) is expected to be issuing its Q3 2026 results before the market opens on Friday, February 6th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Friday, February 6, 2026 at 8:00 AM ET.

Immunovant (NASDAQ:IMVT) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.01). During the same quarter in the previous year, the firm earned ($0.74) EPS. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Stock Performance

IMVT opened at $25.80 on Wednesday. The stock has a market capitalization of $4.52 billion, a PE ratio of -9.08 and a beta of 0.54. Immunovant has a one year low of $12.72 and a one year high of $27.80. The business’s 50 day moving average price is $25.52 and its 200 day moving average price is $20.63.

Insider Buying and Selling at Immunovant

In other news, CTO Jay S. Stout sold 1,977 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $26.03, for a total value of $51,461.31. Following the completion of the transaction, the chief technology officer owned 197,634 shares of the company’s stock, valued at approximately $5,144,413.02. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Andrew J. Fromkin sold 22,249 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $23.25, for a total transaction of $517,289.25. Following the sale, the director directly owned 85,852 shares in the company, valued at approximately $1,996,059. The trade was a 20.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 63,868 shares of company stock valued at $1,538,470. Corporate insiders own 1.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its holdings in Immunovant by 2.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,124 shares of the company’s stock worth $578,000 after purchasing an additional 900 shares during the period. Strs Ohio purchased a new stake in shares of Immunovant during the first quarter worth approximately $27,000. PNC Financial Services Group Inc. raised its holdings in Immunovant by 138.9% in the third quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock valued at $46,000 after acquiring an additional 1,646 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Immunovant by 4.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,641 shares of the company’s stock worth $683,000 after acquiring an additional 1,670 shares during the last quarter. Finally, Swiss National Bank lifted its stake in Immunovant by 2.2% in the third quarter. Swiss National Bank now owns 132,600 shares of the company’s stock worth $2,138,000 after acquiring an additional 2,800 shares during the last quarter. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on IMVT shares. Truist Financial increased their price target on Immunovant from $16.00 to $22.00 and gave the stock a “hold” rating in a report on Thursday, January 8th. Wolfe Research raised shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research note on Tuesday, January 6th. Guggenheim reiterated a “buy” rating and set a $41.00 price target on shares of Immunovant in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a research note on Friday, January 9th. Finally, The Goldman Sachs Group increased their price objective on shares of Immunovant from $18.00 to $28.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunovant presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.78.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.